Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Significant Future Potential, So Says Robert's Son?

<< Previous

Bullboard Posts

Next >>

Comment by ashcakeon Apr 25, 2020 9:11pm

161 Views

Post# 30953977

RE:Significant Future Potential, So Says Robert's Son?

Let's hope his son isn't still in diapers!
will be intersting to see if junior or senior McSquirter prevails in the end. I'm hoping that youth sees through the fog to a better end game for all of us bag holders. Son can likley ne more aggressive playing his pwn money and not clients. either way, I'm all in for a hero or zero result. Cheers all..

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions